In the absence of a co-existent FLT3-ITD (internal tandem duplication), a CEBPA mutation confers a significantly better prognosis in patients with CN-AML [15], with approximately 60% long-term survival, particularly if a “double” (bi-allelic) mutation is found [16]. Here, FLT3 is linked to acute myeloid leukemia.